Eisai’s LEQEMBI IQLIK rollout could unlock a global neuro franchise, but premium valuation, ARIA risk, and execution costs make delivery—not demand—the decisive investment test.
Overview
Eisai is a Tokyo-headquartered, research-driven pharmaceutical company with more than 80 years of therapeutic innovation and a diversified presence across Japan, the Americas, China, EMEA, and East Asia Global South. Prescription pharmaceuticals account for approximately 98.2% of revenue. The investment case is shifting from stable LENVIMA oncology cash flows toward LEQEMBI-led neurodegenerative growth, with DAYVIGO providing a complementary orexin franchise. **The key catalyst is LEQEMBI IQLIK**, a weekly subcutaneous autoinjector approved in the U.S. in mid-2026, China on September 3, 2026, and Japan on September 16, 2026; its at-home format may overcome infusion-center constraints and compete more effectively with Eli Lilly’s IV-only Kisunla.
Q1 FY2026 revenue rose 15.6% to JPY 234.3 billion, operating profit increased 19.2% to JPY 24.7 billion, and net profit rose 26.0% to JPY 18.2 billion. FY2026 guidance remains JPY 883.5 billion of revenue, JPY 70.0 billion of operating profit, JPY 52.3 billion of net profit, and JPY 185.00 EPS. However, the stock trades at 31.8x–32.6x trailing P/E versus a 19.7x pharmaceutical peer average, making valuation dependent on LEQEMBI adoption. The five-year model produces a probability-weighted target of JPY 8,133.50 from JPY 4,765.00.